Navigation Links
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
Date:6/8/2009

President, Global Head, Novartis Oncology Development. "These latest data show an antitumor effect in lymphoma that support the rationale for a Phase III study of Afinitor to prevent relapse in patients with diffuse large B-cell lymphoma, where there is a significant unmet medical need."

Novartis has initiated PILLAR-2 (PIvotaL Lymphoma triAls of RAD001), a Phase III trial investigating adjuvant treatment with everolimus (RAD001) in poor-risk patients with DLBCL who achieved complete remission with first-line rituximab combined with chemotherapy. This worldwide study will evaluate the potential of everolimus to extend disease-free survival in patients with DLBCL. The longer a patient with DLBCL is in remission the higher their likelihood to remain disease-free. There is no approved therapy for the approximately 50% of patients who will relapse after achieving a complete response on initial treatment, demonstrating an important unmet need(6).

EHA study details

The proof-of-concept, open-label, single-arm, multicenter Phase II study was designed to assess the efficacy and safety of everolimus in patients with relapsed/refractory aggressive or indolent NHL or Hodgkin's disease whose disease progressed despite prior treatment. Patients had received a median of four prior therapies (between one and 15 therapies). The study included patients with T-cell non-Hodgkin's lymphoma, Hodgkin's disease, follicular lymphoma, mantle cell lymphoma, DLBCL and small lymphocytic lymphoma; all of whom had experienced disease progression despite prior treatment. The primary endpoint of the study is to assess ORR. Secondary endpoints include assessment of progression-free survival (PFS), overall survival, time to disease progression and the safety profile of Afinitor(1).

In the trial, everolimus showed anticancer activity across multiple types of lymphoma, including T-cell non
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)...  Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical ... virus infections, today announced that Jonathan P. ... of Finance, a newly created role.  Mr. Freve ... including financial planning and reporting, accounting and risk ... , President and CEO. Mr. ...
(Date:2/26/2015)... Israel , Feb. 26, 2015 Integrity ... of the GlucoTrack ® model DF-F, a noninvasive  device ... Lutz Heinemann , Ph.D., will head its new ... opinion leaders in the field of Diabetes research, monitoring ... , Ph.D has been Chief Executive Officer and Head, ...
(Date:2/26/2015)... Feb. 26, 2015 The market for ... is estimated at 2.4 billion in 2014.   ... growth, government insurance, newly insured patients and updated ... and will continue to propel demand.  The healthcare market ... the market and interviews with IVD manufacturers and ...
Breaking Medicine Technology:Jonathan P. Freve, CPA, Joins Spring Bank Pharmaceuticals as Vice President of Finance 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 3Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 4Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 3Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 4
... Calif., Dec. 12, 2011 Since 1994, the Huntington ... of various specialties, has been providing expert medical care ... accepts almost every major health plan and is affiliated ... HMF is the group,s mission to provide a collaborative ...
... 12, 2011 /PRNewswire-iReach/ -- Thomas Ash was ... Ametros as executive vice president in February 2011. Prior ... compensation managed care industry. He served as vice president ... of national occupational health for Kaiser Permanente, division president ...
Cached Medicine Technology:The Huntington Medical Foundation -- Pasadena's Premier Medical Group 2Ametros Financial Names Thomas Ash as CEO 2
(Date:2/26/2015)... Francisco, CA (PRWEB) February 26, 2015 ... the American College of Traditional Chinese Medicine (ACTCM). ACTCM ... starting off with the Chinese New Year celebration and ... event schedule is as follows: , Sunday, March 1 ... 2:30 p.m., ACTCM celebrates the Chinese New Year with ...
(Date:2/26/2015)... When Cosmetic Town launched in 2012, its ... what will soon be, the cornerstone of work that ... of insight that will be accessible to the public, ... has maintained during its existence. Users have more data ... by visiting the Cosmetic Town Journal’s doctor’s page. There ...
(Date:2/26/2015)... 26, 2015 PartnerTech Inc . has ... Makers Awards finalist. , The Movers & ... in the manufacturing, processing, or distribution of tangible products and ... This annual event serves as Georgia’s largest local awards ... to draw more than 300 local industry and business leaders. ...
(Date:2/26/2015)... 26, 2015 Participants in the ... Working? What’s Not? What’s New? ,” will learn ... to achieve strong outcomes for duals-plan members and ... in the implementation phase of programs for Medicare-Medicaid ... Which ones need to be implemented in the ...
(Date:2/26/2015)... 26, 2015 The hip resurfacing procedure ... and Central Texas resident John Short to resume his active ... set out to climb Mt. Kilimanjaro, the highest free-standing mountain ... trafficking. , Starting in his late 20s, Short suffered from ... hip bones and sockets were bone on bone. , ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces March Schedule of Events 2Health News:Cosmetic Town has now Recreated Itself by Adding New Features 2Health News:PartnerTech Named a Finalist for Gwinnett County Chamber of Commerce 2015 Movers & Makers Award 2Health News:PartnerTech Named a Finalist for Gwinnett County Chamber of Commerce 2015 Movers & Makers Award 3Health News:Upcoming AIS Virtual Conference Will Explain What Is and Is Not Working in Medicare-Medicaid Dual Eligibles Programs 2Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 2Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 3
... Association (AGA) Research Foundation has announced the 2011 ... Eli and Edythe Broad Foundation, the awards are ... digestive diseases. "At a time of ... are critical for the future of gastroenterology research, ...
... HealthDay Reporter , WEDNESDAY, June 8 (HealthDay News) -- ... the same time they,re having a uterine aspiration due to ... compared to women offered one later on, new research suggests. ... for IUDs inserted immediately after a uterine aspiration is higher ...
... of "pay-for-performance" bonuses to try to reduce racial and ethnic ... no evidence of the problem at any of the state,s ... questions about the effectiveness of the state,s novel approach. ... Health Affairs (June 9, 2011), found that racial and ...
... as an intrauterine device or IUD immediately following a first ... have an unintended pregnancy than those who delay getting an ... Oregon Health & Science University. The findings are ... Medicine . Research has shown that IUDs are safe, ...
... , WEDNESDAY, June 8 (HealthDay News) -- Jogging, ... protect the brain from "silent strokes," or small brain lesions ... of a future stroke, a new study suggests. "These ... they have been associated with an increased risk of falls ...
... of Sheffield have discovered valuable insight into how people ... in the UK. The team, from the University,s ... Lymphoma Research, Biotechnology and Biological Sciences Research Council (BBSRC) ... to that previously thought to be the cause of ...
Cached Medicine News:Health News:Outstanding high school students receive AGA Research Foundation Fellowship Awards 2Health News:It's Safe to Get IUD Right After Abortion, Miscarriage: Study 2Health News:It's Safe to Get IUD Right After Abortion, Miscarriage: Study 3Health News:Pioneering hospital pay-for-performance program falls short of its goals 2Health News:Immediate use of an IUD following abortion more likely to prevent unintended pregnancies 2Health News:Exercise May Protect the Brain From 'Silent Strokes' 2Health News:New research provides breakthrough in understanding common cancer 2
... FlexSure HP is a visually read, qualitative ... to H. pylori, a bacterium that grows ... peptic ulcer disease and some gastric cancers. ... whole blood or serum samples, provides the ...
Rapid Infectious Mononucleosis Heterophile Antibody (IgM) Test...
Unitary one step immuno-chromatographic assay for the qualitative detection of infectious mononucleosis heterophile antibodies in human serum, plasma or whole blood....
A simple, in-office test for the detection of mononucleosis. Easy to use with fast, accurate results within minutes....
Medicine Products: